Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials

PIERRE LE BLAY, GAEL MOUTERDE, THOMAS BARNETCHE, JACQUES MOREL and BERNARD COMBE
The Journal of Rheumatology April 2012, 39 (4) 712-715; DOI: https://doi.org/10.3899/jrheum.110982
PIERRE LE BLAY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GAEL MOUTERDE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THOMAS BARNETCHE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JACQUES MOREL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BERNARD COMBE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: b-combe@chu-montpellier.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To assess the risk of total malignancy and nonmelanoma skin cancers (NMSC) in patients with rheumatoid arthritis (RA) receiving certolizumab and golimumab through a metaanalysis of data from randomized control trials (RCT).

Methods. We systematically reviewed the literature up to May 2011 in Medline databases, as well as abstracts from the 2009 and 2010 annual meetings of the European League Against Rheumatism and the American College of Rheumatology. Mantel-Haenszel method was used to determine a common odds ratio (OR). Statistical heterogeneity was assessed by chi-square Q test. We selected only RCT including more than 30 RA subjects randomly assigned to an anti-tumor necrosis factor (TNF) or a nonbiological disease-modifying antirheumatic drug (DMARD) control group.

Results. The literature search identified 793 articles; 6 (2 with certolizumab and 4 with golimumab) were selected for metaanalysis. A total of 2710 patients received at least 1 dose of certolizumab or golimumab. For anti-TNF-treated patients, 18 cancers (excluding NMSC) and 9 NMSC were observed versus 4 cases of total malignancy and 3 NMSC in control groups. Metaanalysis revealed a pooled OR of 1.06 (95% CI 0.39–2.85) for risk of total malignancy and 0.69 (95% CI 0.23–2.11) for risk of NMSC with certolizumab and golimumab versus DMARD. Heterogeneity was not significant.

Conclusion. Metaanalysis of RCT of golimumab and certolizumab did not find an increased risk of total malignancy and NMSC. These results must be confirmed with longterm extension studies and registry studies, and careful monitoring remains mandatory.

Key Indexing Terms:
  • CERTOLIZUMAB
  • GOLIMUMAB
  • MALIGNANCY
  • NONMELANOMA SKIN CANCER
  • RHEUMATOID ARTHRITIS
  • METAANALYSIS

For more than 10 years, tumor necrosis factor (TNF) antagonists have shown effectiveness for rheumatoid arthritis (RA) and they are now widely used for treating active RA. In addition to adalimumab, etanercept, and infliximab, 2 new anti-TNF monoclonal antibodies, certolizumab and golimumab, have been approved for RA1,2,3,4,5,6,7,8.

In 2006, a metaanalysis of randomized controlled trials (RCT) of adalimumab and infliximab suggested that these anti-TNF monoclonal antibodies might be associated with an increased risk of malignancy9. However, data including RCT with etanercept did not find a significantly increased risk in patients with RA10. Nevertheless, doubt remains concerning the specific risk for nonmelanoma skin cancers (NMSC) in longterm extension studies11 and in a recent metaanalysis using patient-level data12.

Our objective was to assess the risk of total malignancy and NMSC in patients with RA receiving certolizumab or golimumab; we performed a systematic review and meta-analysis based on data from RCT of those 2 newly licensed anti-TNF products whose results have not been included in previous metaanalyses.

MATERIALS AND METHODS

Study selection

We performed a systematic review of the literature up to May 2011. Bibliographic references were selected from Medline databases and abstracts from 2009 and 2010 annual meetings of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

We searched Medline with PubMed using the following key terms: arthritis, rheumatoid [MeSH] OR rheumatoid arthritis [all fields] AND (neoplasm [MeSH] OR safety [MeSH]) OR (neoplasm or safety) [all fields] AND (biological therapy [MeSH] OR tumor necrosis factor-alpha [MeSH] OR antibodies, monoclonal [MeSH]) OR (monoclonal antibody OR biological response modifier OR tumor necrosis factor-alpha OR tumor necrosis factor alpha antibody OR tumor necrosis factor-alpha OR anti tumor necrosis factor) [all fields] OR certolizumab pegol [all fields] OR golimumab [all fields] OR (Drug Combination Disease (W) Modifying (W) Anti (W) Inflammatory (W) Drug OR Dmard) [all fields]. In addition, reference lists of the reports initially identified were manually searched to identify additional relevant reports.

To be included, RCT of golimumab and certolizumab had to include more than 30 RA subjects in intention-to-treat studies, randomly assigned to an anti-TNF or a nonbiological DMARD control group for at least 10 weeks. Studies with a placebo control group and treatment arms of combination biological therapies were excluded.

Total malignancy was considered as all solid (including melanoma and excluding NMSC) and hematological cancers. NMSC included basal and squamous cell skin cancers.

Statistical analysis

The pooled odds ratio (OR) for patients receiving certolizumab or golimumab versus synthetic disease-modifying antirheumatic drug (DMARD) therapy was determined using Mantel-Haenszel methods, with a continuity correction designed for sparse data (adding 0.5 to each arm of such studies). Moreover, additional sensitivity analyses were conducted, describing the stability of the results when either 1 or 2 “virtual” events were used in case no cancer event had been observed in the trials.

Analyses involved use of Revman 5.0 software developed by the Nordic Cochrane Center. OR and 95% CI are shown on forest plots. Statistical heterogeneity was assessed by the chi-square Q test, with a significance level of 0.05.

RESULTS

The literature search identified 793 articles, from which 72 were preselected on the basis of the title and abstract. After reading full texts, we selected 6 RCT with a synthetic DMARD comparison group, 2 with certolizumab6,8, and 4 with golimumab1,2,3,4 (Figure 1). A total of 2710 patients received at least 1 dose of certolizumab or golimumab, compared with 783 who received synthetic DMARD. For patients treated with anti-TNF inhibitors, 18 cancers were observed (excluding NMSC): 2 each breast, tongue, colon, and lung cancers; 1 each uterus, esophageal, liver, adrenal, papilloma, testicle, bladder, and ovarian cancers; and 2 hematological neoplasms. Only 4 cases of malignancy were observed in control groups. A metaanalysis of data from these 6 studies with patients receiving synthetic DMARD as control group revealed a pooled OR for risk of total malignancy with certolizumab and golimumab of 1.06 (95% CI 0.39–2.85) versus DMARD, without significant heterogeneity (Figure 2).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The selection process of articles.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Risk estimates of total malignancy (excluding nonmelanoma skin cancers) reported in randomized controlled trials of patients with rheumatoid arthritis treated with golimumab and certolizumab. TNF: tumor necrosis factor; DMARD: disease-modifying antirheumatic drug; M-H: Mantel-Haenszel test.

Nine cases of NMSC were observed in anti-TNF groups, compared with 3 in DMARD groups, and the pooled OR was 0.69 (95% CI 0.23–2.11; Figure 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Risk estimates of nonmelanoma skin cancers reported in randomized controlled trials of patients with rheumatoid arthritis treated with golimumab and certolizumab. TNF: tumor necrosis factor; DMARD: disease-modifying antirheumatic drug; M-H: Mantel-Haenszel test.

Sensitivity analyses did not significantly modify our results, as the same trend toward no significantly increased risk was observed (data not shown).

DISCUSSION

A relation between RA and carcinogenesis was suggested for many years because some registry studies found an increased risk of certain cancers (lung, lymphoma, NMSC) in patients with RA as compared with the general population, regardless of the treatment13,14.

Recently, Leombruno, et al10, in a metaanalysis, analyzed 17 RCT of adalimumab, etanercept, and infliximab compared to DMARD in RA. The OR was 1.34 (95% CI 0.75–2.39) for total malignancy. Askling, et al12, in another metaanalysis of RCT of these 3 TNF antagonists in RA (31 RCT) and other diseases (43 RCT), used a strict method listing different types of malignancy, with predefined terms that were as specific as possible irrespective of report in the trial, in order to reduce missing information. They did not find an increased risk of total malignancy, but the risk of NMSC was significantly higher with TNF antagonists (HR 2.02, 95% CI 1.11–3.95)12.

In order to complete the metaanalysis of these 3 widely used TNF antagonists, and because few RCT of these biologics had been recently published, we aimed to assess the risk of malignancy especially with 2 new monoclonal antibodies by performing a metaanalysis of data from RCT of these 2 drugs. We chose to pool total malignancy (without NMSC) as 1 group and NMSC-only as the other, because of observations of a possible increased risk of NMSC with TNF antagonist treatment11,12 and differences in prognosis of these cancers. This distinction had been made in previous metaanalyses10,12. We excluded placebo-control trials in order to compare the risk of malignancy with these 2 new TNF antagonists with the “gold standard” in RA. Data extracted from RCT enable a strict comparison with referent treatment and a comprehensive inventory of safety. However, because of their short followup (only 2 studies had data at 52 weeks and one at 48 weeks; the others were 24-week followup studies) and small sizes of different groups, RCT are limited in assessing uncommon adverse effects such as cancer. This is a significant bias for safety analysis we found in all metaanalyses of RCT.

This first metaanalysis of risk of malignancy with use of certolizumab and golimumab is reassuring, as we found no increased risk of total malignancy and NMSC. However, these results must be confirmed with longterm extension studies and registry studies, and careful monitoring remains mandatory.

  • Accepted for publication November 9, 2011.

REFERENCES

  1. 1.↵
    1. Emery P,
    2. Fleischmann RM,
    3. Moreland LW,
    4. Hsia EC,
    5. Strusberg I,
    6. Durez P,
    7. et al.
    Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272–83.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kay J,
    2. Matteson EL,
    3. Dasgupta B,
    4. Nash P,
    5. Durez P,
    6. Hall S,
    7. et al.
    Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964–75.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kremer J,
    2. Ritchlin C,
    3. Mendelsohn A,
    4. Baker D,
    5. Kim L,
    6. Xu Z,
    7. et al.
    Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917–28.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Keystone EC,
    2. Genovese MC,
    3. Klareskog L,
    4. Hsia EC,
    5. Hall ST,
    6. Miranda PC,
    7. et al.
    Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789–96.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Smolen J,
    2. Kay J,
    3. Doyle M,
    4. Landewe R,
    5. Matteson EL,
    6. Wollenhaupt J,
    7. et al.
    Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210–21.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Smolen J,
    2. Landewe RB,
    3. Mease P,
    4. Brzezicki J,
    5. Mason D,
    6. Luijtens K,
    7. et al.
    Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797–804.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Fleischmann R,
    2. Vencovsky J,
    3. Van Vollenhoven RF,
    4. Borenstein D,
    5. Box J,
    6. Coteur G,
    7. et al.
    Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann Rheum Dis 2009;68:805–11.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Keystone E,
    2. Heijde D,
    3. Mason D,
    4. Landewe R,
    5. van Vollenhoven R,
    6. Combe B,
    7. et al.
    Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–29.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Bongartz T,
    2. Sutton AJ,
    3. Sweeting MJ,
    4. Buchan I,
    5. Matteson EL,
    6. Montori V
    . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Leombruno JP,
    2. Einarson TR,
    3. Keystone EC
    . The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136–45.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Burmester GR,
    2. Mease P,
    3. Dijkmans BA,
    4. Gordon K,
    5. Lovell D,
    6. Panaccione R,
    7. et al.
    Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863–9.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Askling J,
    2. Fahrbach K,
    3. Nordstrom B,
    4. Ross S,
    5. Schmid CH,
    6. Symmons D
    . Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119–30.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Geborek P,
    2. Bladström A,
    3. Turesson C,
    4. Gulfe A,
    5. Petersson IF,
    6. Saxne T,
    7. et al.
    Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699–703.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Askling J,
    2. Fored CM,
    3. Brandt L,
    4. Baecklund E,
    5. Bertilsson L,
    6. Feltelius N,
    7. et al.
    Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421–6.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 4
1 Apr 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
PIERRE LE BLAY, GAEL MOUTERDE, THOMAS BARNETCHE, JACQUES MOREL, BERNARD COMBE
The Journal of Rheumatology Apr 2012, 39 (4) 712-715; DOI: 10.3899/jrheum.110982

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with Rheumatoid Arthritis: Metaanalysis of Randomized Controlled Trials
PIERRE LE BLAY, GAEL MOUTERDE, THOMAS BARNETCHE, JACQUES MOREL, BERNARD COMBE
The Journal of Rheumatology Apr 2012, 39 (4) 712-715; DOI: 10.3899/jrheum.110982
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire